Garetosmab
Medium EvidenceGaretosmab (REGN2477) is Regeneron's investigational fully human anti-activin A monoclonal antibody. In the Phase 3 OPTIMA trial in adults with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), it cut new heterotopic bone lesions by ~90-94% and reduced new-lesion volume by >99% versus placebo; its BLA was accepted for FDA Priority Review with an August 2026 target action date. The same activin A blockade also makes garetosmab the muscle-preserving partner to trevogrumab and semaglutide in the Phase 2 COURAGE obesity program.
What It Is
Garetosmab (REGN2477) is a VelocImmune-derived, fully human monoclonal antibody that binds and neutralizes activin A, a TGF-beta-superfamily protein that Regeneron scientists identified as a key driver of abnormal bone growth in fibrodysplasia ossificans progressiva (FOP). FOP is a relentless, ultra-rare genetic disorder - roughly 900 diagnosed cases worldwide - in which mutations in the ACVR1 (Activin A receptor type I) gene reprogram the receptor so that activin A, which normally does not trigger bone formation, instead drives heterotopic ossification (HO): new bone that infiltrates muscles, tendons, ligaments and other soft tissues. Progressive HO of the jaw, spine, hip and rib cage makes it difficult to speak, eat, walk and breathe; most people with FOP are wheelchair-bound by age 30 and median survival is about 56 years. By soaking up activin A, garetosmab is designed to shut off the signal at the top of that cascade. In the Phase 3 OPTIMA trial (63 adults aged 18+ with active FOP), both doses were highly efficacious: on the primary endpoint - reduction in the total number of new HO lesions at 56 weeks versus placebo (n=21) - the 3 mg/kg arm (n=19) showed a 94% reduction (1 lesion vs 19; p=0.0274) and the 10 mg/kg arm (n=23) a 90% reduction (2 lesions vs 19; p=0.0260). A post-hoc analysis found both doses reduced the mean total volume of new HO lesions by more than 99% (0.01 cm3 and 0.02 cm3 vs 10.45 cm3 for placebo). Serious treatment-emergent adverse events at 56 weeks were rare and balanced (1 patient on 3 mg/kg, 2 on 10 mg/kg, 2 on placebo), with no treatment-related deaths reported in OPTIMA; the most common adverse reactions (incidence >=30%) were epistaxis (nosebleeds), increased hair growth, abscess and acne. On February 19, 2026, the FDA accepted the garetosmab Biologics License Application for Priority Review with a target action date of August 2026; if approved it would be the first and only treatment shown to reduce the number and volume of new HO lesions in adults with FOP. Garetosmab holds FDA Fast Track and Orphan Drug designations and EU Orphan designation, and a pediatric Phase 3 (OPTIMA 2) is planned. Beyond FOP, activin A is a muscle-atrophy and metabolic signal, which is why garetosmab is being tested as the anti-activin-A partner to the anti-myostatin antibody trevogrumab in Regeneron's Phase 2 COURAGE obesity trial: the semaglutide + trevogrumab + garetosmab triplet reached ~13.4% total weight loss at 26 weeks while preserving more than 80% of lean body mass, with garetosmab boosting fat-mass loss by ~27.3% over semaglutide alone. Garetosmab is investigational and not approved for any indication.
Regulatory Status
Garetosmab's Biologics License Application for adults with FOP was accepted for FDA Priority Review on February 19, 2026, supported by the Phase 3 OPTIMA trial; the target action date for the FDA decision is August 2026. Garetosmab holds FDA Fast Track and Orphan Drug designations and EU Orphan designation. It is also being studied as a muscle-preserving add-on in the Phase 2 COURAGE obesity trial. Not approved for any indication.
Effective: February 2026
View FDA SourceWhy Researchers Study It
Garetosmab is a rare thing in FOP - a therapy that appears to shut off the disease's core driver rather than manage its consequences. By neutralizing activin A, the ligand Regeneron showed is hijacked by the mutant ACVR1 receptor to build heterotopic bone, garetosmab reduced new bone lesions by ~90-94% and their volume by >99% in Phase 3, offering the first potential disease-modifying option for a disorder that otherwise progressively immobilizes patients. The same biology makes it a probe of activin A's broader roles: because activin A is also a muscle-wasting and metabolic signal, garetosmab lets researchers test whether blocking it - on top of myostatin blockade with trevogrumab - can protect lean mass and deepen fat loss during GLP-1 (semaglutide) weight loss, dissecting the distinct contributions of the activin A and myostatin (GDF-8) pathways to muscle biology.
Proposed Mechanisms
- Binds and neutralizes circulating activin A, blocking the ligand that the mutant ACVR1 receptor in FOP uses to drive heterotopic ossification (new soft-tissue bone)
- Halts abnormal bone formation upstream, reducing the number and volume of new heterotopic ossification lesions rather than treating flare-ups after they occur
- In obesity, blocks activin A as a muscle-atrophy signal - complementing myostatin (GDF-8) blockade by trevogrumab to preserve lean mass during GLP-1-induced weight loss
- Adding activin A blockade shifts the composition of weight lost toward fat, enhancing fat-mass reduction while sparing muscle
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (OPTIMA) - randomized, double-blind, placebo-controlled | 63 adults (18+) with active FOP; 3 mg/kg or 10 mg/kg garetosmab or placebo IV every 4 weeks for 56 weeks | Primary endpoint - new HO lesions vs placebo (n=21): 3 mg/kg (n=19) 94% reduction (1 vs 19 lesions; p=0.0274); 10 mg/kg (n=23) 90% reduction (2 vs 19; p=0.0260) | Source |
| Phase 3 (OPTIMA) - post-hoc volume analysis, 56 weeks | Mean total volume of new HO lesions by CT vs placebo | >99% reduction in new-lesion volume both doses (3 mg/kg: 0.01 cm3 vs 10.45 cm3, nominal p=0.0013; 10 mg/kg: 0.02 cm3 vs 10.45 cm3, nominal p=0.0005) | Source |
| Phase 2 (COURAGE, NCT06299098) - obesity, triplet arm, 26 weeks | Semaglutide + trevogrumab (anti-myostatin) + garetosmab (anti-activin A) vs semaglutide alone | Triplet reached ~13.4% total weight loss with only ~7.4% of loss from lean mass and >80% lean mass preserved; garetosmab boosted fat-mass reduction ~27.3% over semaglutide alone | Source |
| Phase 2 (LUMINA-1) - earlier FOP trial (context/safety) | 44 adults with FOP; garetosmab vs placebo (28-week blinded), then open-label extension | Substantially reduced new HO lesions and flare-ups; 5 of 44 deaths occurred in the open-label period (considered unlikely related), prompting a 2020 FDA clinical hold that led to the redesigned Phase 3 OPTIMA program | Source |
Commonly Discussed Benefits
Researching Garetosmab? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational - not approved for any indication; FOP BLA is under FDA Priority Review with an August 2026 target action date, and approval is not guaranteed
- Efficacy figures are from company press releases on the Phase 3 OPTIMA trial; full peer-reviewed OPTIMA publication and long-term/pediatric data are still emerging
- FOP is ultra-rare (~900 diagnosed worldwide); the OPTIMA trial was small (63 adults), which limits precision and generalizability
- The earlier Phase 2 (LUMINA-1) saw 5 of 44 deaths during its open-label period and a 2020 FDA clinical hold; the deaths were judged unlikely related to garetosmab and no treatment-related deaths were reported in OPTIMA, but the history warrants careful long-term safety follow-up
- Common adverse reactions include epistaxis (nosebleeds), increased hair growth, abscess and acne, reflecting activin A / BMP-axis biology
- Obesity/muscle-preservation use (COURAGE) is early Phase 2; activin A-blocking arms have carried a heavier side-effect burden than anti-myostatin or GLP-1 therapy alone
Comparisons
See how Garetosmab compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - Regeneron (February 19, 2026) PubMed
- [2] Regeneron Announces Positive Phase 3 Trial in Adults with FOP, Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation - Regeneron PubMed
- [3] Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial (LUMINA-1) - Nature Medicine (2023) PubMed
- [4] Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 Receptor Agonist-induced Weight Loss by Preserving Lean Mass - Regeneron (September 2025) PubMed
Keep researching in the app
- Log Garetosmab to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
CAP-GDF15
Low EvidenceA newly discovered 12-amino acid anorexigenic peptide derived from the GDF15 prepropeptide region, representing a novel appetite-suppression pathway.
Bimagrumab
Medium EvidenceAn anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity.
Taldefgrobep Alfa
Low EvidenceA novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026.
Apitegromab
Low EvidenceApitegromab (SRK-015) is an investigational, fully human IgG4 monoclonal antibody developed by Scholar Rock that inhibits myostatin - the muscle-produced growth factor that limits skeletal-muscle mass - through a novel, muscle-selective mechanism. Rather than neutralizing mature, active myostatin (the approach of earlier failed inhibitors), apitegromab binds only the inactive precursor forms of the protein - promyostatin and latent myostatin - stored locally in muscle, and blocks their proteolytic conversion into the active ligand. Because it spares the closely related growth factors activin A, BMP9/10, and TGF-beta1, it aims to avoid the off-target effects (such as bleeding and vascular changes) that sank broad ActRII-pathway drugs. Apitegromab is the first muscle-targeted therapy to succeed in a pivotal Phase 3 trial in spinal muscular atrophy (SMA): in the 156-patient SAPPHIRE study of nonambulatory Type 2/3 patients aged 2-12 already on an SMN-directed therapy (nusinersen or risdiplam), adding apitegromab (10 or 20 mg/kg IV every 4 weeks) improved motor function by a pooled 1.8 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo at 12 months (p=0.019). Scholar Rock's initial Biologics License Application received an FDA Complete Response Letter in September 2025 tied solely to a third-party (Catalent Indiana) fill-finish manufacturing inspection - not to the drug's efficacy or safety - and the company resubmitted the BLA on March 31, 2026, with a PDUFA target action date of September 30, 2026. In parallel, apitegromab produced positive Phase 2 obesity data (EMBRAZE): added to tirzepatide over 24 weeks it preserved about 55% more lean mass (roughly 1.9 kg / 4.2 lb) than tirzepatide alone, positioning myostatin inhibition as a potential lean-mass-sparing partner for GLP-1-based weight loss.
Trevogrumab
Medium EvidenceTrevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass.
Sotatercept
High EvidenceSotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025.
Abaloparatide
High EvidenceAbaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.